Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxetumomab Pasudotox in Pediatric B-ALL with MRD
NCT02338050Phase 2Terminated
- Sponsor
- Center for International Blood and Marrow Transplant Research
- Start
- May 2015
- Primary completion
- May 2020
- Modality
- Antibody Fragments, Immunotoxins, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of moxetumomab pasudotox in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Center for International Blood and Marrow Transplant Research. Primary endpoint: Minimal Residual Disease Negativity. Started May 2015; status: terminated.
02
Drugs
moxetumomab pasudotox
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02338050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338050.